In March 2023, Japan’s Ministry of Health and Labor Welfare approved Novo Nordisk’s once-weekly subcutaneous glucagon-like peptide-1
Marketing Authorization replaces conditional Marketing Authorization and is first for Novavax in the EU
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
Pfizer is likely to show GSK significant competition
The company moves a step closer towards achieving its goal of emerging as the top oncology medicine supplier from India in the ASEAN region
Subscribe To Our Newsletter & Stay Updated
